Baxter Healthcare Corporation

Baxter Healthcare Corporation
Share

DEERFIELD, Ill., February 6, 2018 — Baxter International Inc. (NYSE: BAX) will present at the Raymond James & Associates 39th Annual Institutional Investors Conference on Tuesday, March 6, 2018, in Orlando, Fla. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 4:35 p.m. EST. The live webcast of Baxter’s presentation, can...

DEERFIELD, Ill, January 25, 2018 — Baxter International Inc. (NYSE: BAX) will present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21, 2018, in New York. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:30 a.m. Eastern Standard Time. The live webcast of Baxter’s presentation, can...

First presentation of bivalirudin in frozen, premixed, ready-to-use formulation DEERFIELD, Ill., January 22, 2018 – Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection...

DEERFIELD, Ill., January 17, 2018 — Baxter International Inc. (NYSE: BAX) will present at the 7th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 14, 2018, in New York. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 11:30 a.m. Eastern Standard Time. The live webcast of Baxter’s presentation...

Intravenous administration of a solution containing sterile particulate matter may lead to adverse health consequences. The extent and severity of harm depends on the size, number and composition of the foreign material, and the patient’s underlying medical condition. In the absence of in-line filtration, these particles may cause local vein irritation...

Helps ensure safer drug preparation, transportation, administration and disposal
Helps support compliance with NIOSH and upcoming standards
DEERFIELD, Ill., January 11, 2018 – Baxter International Inc. (NYSE: BAX), a leader in innovative technology for medication delivery, today announced a distribution agreement for the U.S. launch of the...

Proposed acquisition includes two pioneering hemostat and sealant products, including the first and only stand-alone recombinant thrombin and a surgical sealant Products expand Baxter's portfolio of surgical solutions to address intraoperative bleeding and increase surgeons' options
DEERFIELD, Ill., JANUARY 8, 2018 – Baxter International Inc....

Baxter Healthcare Corporation

 •  December 5, 2017

DEERFIELD, Ill., December 4, 2017 — Baxter International Inc. (NYSE: BAX) will present at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017, in New York at 11:30 a.m. Eastern Standard Time. The live webcast of Baxter’s presentation, along with accompanying slides, can be accessed at...

Baxter Healthcare Corporation

 •  November 15, 2017

DEERFIELD, Ill., November 14, 2017 – Baxter International Inc. announced today it is voluntarily recalling one lot of NEXTERONE (amiodarone HCl) 150 mg/100 mL Premixed Injection – distributed between 6/23/2017 and 10/2/2017 in the United States to wholesalers/distributors and healthcare facilities – due to the potential presence of particulate...

Baxter Healthcare Corporation

 •  November 15, 2017

DEERFIELD, Ill., November 14, 2017 — Baxter International Inc. (NYSE: BAX) will present at the Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, in New York. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 7:30 a.m. Eastern Standard Time. The live webcast of Baxter’s presentation can be accessed at...